Skip to main content

Table 6 Clinical performance of triaging all hrHPV+ women with LBC

From: Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies

Study Sensitivity (CIN2+) Specificity (CIN2+) Relative cost of Comparator 1
ATHENA (Castle PE et al., 2011 [28]) 88.2% 57.8% − 24%
POBASCAM (Dijkstra M et al., 2013 [32]) 66% 81.4% −26%
PavDag (Stanczuk GA. et al., 2017 [33]) 68.3% 89.1% − 26%